在患有严重充血性心力衰竭的患者中,尼托普鲁西德和区域血管容量
C Risöe1, S Simonsen, K Rootwelt
1Medical Department B, Rikshospitalet, Oslo, Norway.
Circulation
|March 1, 1992
概括
酸活跃放松肠道和肺部容量血管,降低严重充血性心力衰竭患者的静脉压力. 肝血管体积可能由于压力降低而被动减少.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 调查严重充血性心力衰竭 (CHF) 患者 (NYHA 第四类) 肺高血压中酸的作用.
- 评估对区域血管容量的影响.
研究的目的:
- 为了确定酸对严重心血管衰竭和肺高血压患者的区域血管容量的影响.
- 为了阐明由酸引发的血管体积变化的机制.
主要方法:
- 平衡血池光学扫描用于测量区域血液体积 (平衡,肺).
- 肝静脉压力和肺动脉压力测量以评估扩张压力.
- 酸的剂量升级,直到静脉肺动脉压力降至低于50mmHg.
主要成果:
- 酸显著降低了大动脉,肺毛细血管和肝静脉压力的平均值.
- 肠道血液体积显著增加 (26%),而肝脏血液体积减少 (9%). 肺部血液体积保持不变.
- 压力-体积分析表明肠道和肺部容量血管的活性放松.
结论:
- 化有效地降低了CHF患者的静脉压力,通过肠道和肺部容量血管的活性放松.
- 肝血管体积减少可能是静脉压力下降的被动后果.
更多相关视频
相关概念视频
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


